Valvular dysfunction and age go hand in hand,” Dr. Raza explained. “In the general population, 2% of patients have valvular ...

A new method of alerting clinical care providers holds promise for increasing treatment and improving survival for patients ...

A new method of alerting clinical care providers holds promise for increasing treatment and improving survival for patients with severe aortic stenosis (AS), a valvular heart condition that can be ...

The DapaTAVI trial assessed the benefits of dapagliflozin in patients discharged after TAVI with a history of heart failure plus 1 of the following comorbidities: LVEF ≤40%, diabetes, or renal ...

The cause of death for Skyview football player William Sloan was sudden cardiac death brought on by natural causes, the Clark ...

A new method of alerting clinical care providers holds promise for increasing treatment and improving survival for patients with severe aortic ...

Patients with heart failure who took dapagliflozin, a sodium-glucose co-transporter-2 (SGLT-2) inhibitor, after undergoing transcatheter aortic valve replacement (TAVR) were significantly less likely ...

Patients who underwent transcatheter aortic valve replacement (TAVR) with a valve designed to treat aortic regurgitation had ...

Eli Lilly’s experimental drug, lepodisiran, reduces lipoprotein(a) (Lp[a]) levels by an average of 93.9 per cent in a ...

Researchers found that a gene on the Y chromosome influences how aortic valve stenosis progresses differently in males and ...

A new method of alerting clinical care providers holds promise for increasing treatment and improving survival for patients ...